BioMarin
BMRN
Performance
About BioMarin
BioMarin is a global biotechnology company that develops medicines to treat rare genetic conditions and lysosomal storage diseases. The company focuses on therapies for conditions such as achondroplasia and severe hemophilia A, with a broad portfolio of eight marketed products and an advancing pipeline across research and development, manufacturing, and clinical trials. Since its founding in 1997, BioMarin has established a worldwide presence and ongoing patient support programs, with operations and information accessible to patients and healthcare professionals globally.
Recent News
5 FDA Decisions to Watch in the First Quarter of 2026
First-Movers Respond to Herding; BioMarin Vets Start New Biotech; GSK Buys RAPT Therapeutics; and More
BioCentury’s 2025-26 Picks and Predictions. Plus: BioMarin and More Biotech ICYMI — a BioCentury Podcast
Korea’s Ildong Promotes Chae Joon Lee to Co-CEO
BioMarin Vets Spearhead New Biotech with $82M for Rare Disease Drugs
11 Companies Hiring Manufacturing Professionals Now
FDA Grants Full Approval to Travere’s FILSPARI for FSGS, Unlocking $2B Market
Novo Nordisk, BioMarin Make AI Moves; Bristol Myers Welcomes Neurology Exec From Eisai
Game Over- No Self-Help Clock Reset for Mandatory Stay Request
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
Yuviwel Gets FDA Greenlight as First Once‑Weekly Treatment for Dwarfism in Children
Bone Disease Readout Sinks Mereo, Ultragenyx Shares: Clinical Roundup
Moderna Licenses Phase 3 Asset to Recordati; ProMIS' Private Placement
Seeking ‘Continuous’ Run of Deals, BioMarin Adds Fabry, Pompe Drugs via $4.8B Amicus Takeout
The Top 12 Companies Hiring in Biopharma Now
Scaling RNA Therapeutics Sustainably Using the ECO Synthesis Manufacturing Platform
Recent Deals
No recent deals for this company.
